企業プロフィール
DBV Technologies 株価・ニュース・カタリスト
- ティッカー:
- DBVT
- 取引所:
- NASDAQ
- セクター:
- Biopharma
- 所在地:
- France
株価パフォーマンス
11.21 USD (-4.68%)
終値
最終更新: 2026年10月1日
1.08B USD
時価総額
株価変動の要因
2026年10月1日 時点で DBVT は 4.68% 下落し、$11.21 で取引を終えました。現在のニュース監視期間内に同社の新しいニュースは確認されませんでした。
企業概要
Food-Allergy Immunotherapy Company
DBV Technologies is developing treatments for food allergy using epicutaneous immunotherapy. Its programs are designed to deliver small quantities of allergen through intact skin with the goal of desensitizing patients while limiting systemic exposure.
Viaskin Patch Platform
The Viaskin patch places allergen on the skin, where it is taken up by immune cells without requiring an injection or oral dose. The approach is intended to offer a convenient, non-invasive treatment format suitable for young children.
Viaskin Peanut in Children
The lead program, Viaskin Peanut, is being developed for peanut-allergic children aged four through seven years. The registration package is supported by the pivotal Phase 3 VITESSE study and is being prepared for U.S. regulatory submission.
Toddler and Infant Development
DBV is extending Viaskin Peanut into younger age groups through the COMFORT Toddlers safety study in children aged one through three years and the THRIVE study in peanut-allergic infants aged six through twelve months. This lifecycle strategy could broaden the addressable population across early childhood.
Allergy-Specialist Commercial Model
If approved, Viaskin Peanut would be marketed through allergists and other specialists who manage pediatric food allergy. DBV is building U.S. medical, safety, regulatory, supply-chain, and commercial capabilities while producing pre-commercial inventory.
今後のカタリスト
- U.S. BLA submission for Viaskin Peanut in children aged four through seven years in the third quarter of 2026.
最近のニュース
ニュースタイトルは機械翻訳です。詳細は英語の原文をご覧ください。
- 01
- 02
- 03
- 04
- 05
類似銘柄
事業成熟度、治療領域、カタリスト傾向が近い同業銘柄です。